Boardroom Alpha
Boardroom Alpha
NERV · Additional Proxy Materials (DEFA14A) · Filed April 23, 2026

Minerva Neurosciences Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 23, 2026
Ticker
NERV
Accession
0001193125-26-171805
Boardroom Alpha · Filing insights

Minerva Neurosciences' board urges shareholders to elect two Class III directors, Kupfer and van Heek, at the 2026 annual meeting.

About Minerva Neurosciences Inc
Market cap
$239M
1Y TSR
+109.2%
3Y TSR
−21.5%
Board grade
C+
Sector
Healthcare
CEO
Remy Luthringer
Last annual meeting: Jun 3, 2026 · View full Minerva Neurosciences Inc profile →
DEFA14A

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.  )

 

 

Filed by the Registrant ☒    Filed by a party other than the Registrant ☐

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under § 240.14a-12

MINERVA NEUROSCIENCES, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required

 

Fee paid previously with preliminary materials

 

Fee computed on table in exhibit required by Item  25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


LOGO

Your Vote Counts!MINERVA NEUROSCIENCES, INC.1500 DISTRICT AVEBURLINGTON, MA 01803MINERVA NEUROSCIENCES, INC.2026 Annual MeetingVote by June 2, 202611:59 PM ETYou invested in MINERVA NEUROSCIENCES, INC. and it’s time to vote!You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding theavailability of proxy materials for the stockholder meeting to be held on June 3, 2026.Get informed before you voteView the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) byrequesting prior to May 20, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings,you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending anemail, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive apaper or email copy.For complete information and to vote, visit www.ProxyVote.comControl #Vote Virtually at the Meeting*June 3, 20268:30 AM EDTSmartphone usersPoint your camera here andvote without entering acontrol number*Please check the meeting materials for any special requirements for meeting attendance.


LOGO

THIS IS NOT A VOTABLE BALLOTThis is an overview of the proposals being presented at theupcoming stockholder meeting. Please follow the instructions onthe reverse side to vote these important matters.Vote at www.ProxyVote.comPrefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.Voting ItemsBoardRecommendsV94044-P483771. To elect two Class III directors each to hold office until 2029 Annual Meeting of Stockholders.Nominees: For01) David Kupfer02) Jan van Heek2. To approve an amendment of the Company’s Amended and Restated Certificate of Incorporation, as amended (the“Existing Charter”), to reflect Delaware Law provisions allowing for the exculpation of certain officers. For3. To approve an amendment of the Existing Charter to eliminate the exclusive forum provision. For4. To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in theaccompanying proxy statement. For5. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of theCompany’s named executive officers. 1 Year6. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independentregistered public accounting firm of the Company for its fiscal year ending December 31, 2026. ForNOTE: The proxies are authorized to vote in their discretion on such other business as may properly come before themeeting or any adjournment or postponement thereof.Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.V94044-P48377

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Minerva Neurosciences Inc (NERV)

Reference

Frequently asked questions

When did Minerva Neurosciences Inc file this DEFA14A?
Minerva Neurosciences Inc (NERV) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 23, 2026. The accession number assigned by EDGAR is 0001193125-26-171805.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Minerva Neurosciences' board urges shareholders to elect two Class III directors, Kupfer and van Heek, at the 2026 annual meeting. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Minerva Neurosciences Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Minerva Neurosciences Inc has filed under CIK 1598646, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer